Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Afimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Afimmune Initiates Epeleuton Phase IIb TRIAGE Study in Patients With High Triglycerides and Type 2 Diabetes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Afimmune"}]

Afimmune

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Afimmune Initiates Epeleuton Phase IIb TRIAGE Study in Patients With High Triglycerides and Type 2 Diabetes

Details:

TRIAGE is a dose finding Phase IIb study being conducted in Germany, Israel, Latvia, Switzerland and the United States to assess the efficacy and safety of orally administered epeleuton in 240 patients with hypertriglyceridemia and type 2 diabetes.

Lead Product(s): Epeleuton

Therapeutic Area: Cardiology/Vascular Diseases Product Name: DS102

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 23, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY